Jiangsu Otsuka

Jiangsu Otsuka Pharmaceutical Co., Ltd. is a prominent pharmaceutical joint venture established in 1981 between Japan's Otsuka Pharmaceutical and China National Pharmaceutical Group (Sinopharm). As the first Sino-foreign joint venture in the Chinese pharmaceutical industry, the company has played a vital role in introducing international manufacturing standards to the region. It specializes in the production of large-volume parenterals, including intravenous solutions and clinical nutrition products. The company's portfolio features well-known products such as Amiparen and various electrolyte injections designed for fluid replacement and metabolic support. Based in Wuxi, Jiangsu, the company operates high-capacity GMP-certified facilities to serve hospitals and healthcare providers across China.